Gilead faces securities fraud claims; Europe weighs Tysabri label change

> On the same day that the FDA approved Gilead Sciences' anti-HIV drug Viread for hepatitis B treatment, a federal appeals court reinstated a securities-fraud suit that claims the company inflated its stock price by illegally marketing unapproved uses of that drug, including for hepatitis B treatment. Report

> Europe's pharma regulators say they're assessing the two reports of brain disease in patients taking the Biogen Idec/Elan multiple sclerosis med Tysabri to determine whether to update the drug's label. Report

> Elan has received first-round bids for its drug delivery business Elan Drug Technologies, and is hoping for a quick sale. Report

> Sanofi-Aventis sued Canadian generic-drug maker Apotex, which is planning to sell a low-cost version of the cancer drug Taxotere in the U.S. Report

> Biovail swung to a $25.3 million loss in the second quarter, weighed down by declining revenue and charges related to its shift in focus to central nervous system disorders. Report

> A combination of two cheap existing drugs -- the chemo med doxorubicin andn osteoporosis drug zoledronic acid -- could offer a new method of treating breast cancer. Report

> St. Jude Medical got the FDA nod to sell a neurostimulation device, EonC, for treating chronic pain. Report

> Shire has accumulated 81 percent of the shares in Germany's Jerini since July 3, when the British company announced its bid; today, Shire published a new offering document for the remaining shares. Report

> India's Sun Pharma got the FTC's approval to buy Taro Pharmaceuticals provided Sun sells the rights to three generic formulations of a commonly used epilepsy med. Report

> West Virginia is the most medicated state in the U.S., using more retail prescription meds per capita than any other state, according to a ranking in Forbes. Report

> Sanofi-Aventis and Bristol-Myers Squibb said they approve of the U.K.'s announced review of its treatment protocols on cardiovascular disease. Release

> South Africa's health department is investigating the recent withdrawal of two tuberculosis meds supplied by Pharmascript; it's the second recall in less than a week of substandard meds in that country. Report

> An investigative team at Johns Hopkins has been studying a woman whose natural immunity has quelled the virus she was infected with 10 years ago. Report

> A team of scientists at Newcastle University is preparing a small human trial to test a one-shot approach to curing rheumatoid arthritis with a vaccine devised from a patient's white blood cells. Report

> H5N1 isn't the only avian virus that threatens to trigger a pandemic. A group of virologists was able to make an H9 virus much more transmissible by changing a single chemical component in the hemagglutinin protein, which allows the virus to attach to cells. Report

> Scientists at the University of Michigan are moving closer to human trials of a new nanoemulsion hepatitis B vaccine that could revolutionize therapy in the third world. Report

> As expected, Genentech turned down Roche's $43.7 billion bid for all outstanding shares, but made it clear that a sweetened offer could win a nod. Report

> Looking to elbow its way to a larger share of the global plasma product market, Australia's CSL has agreed to buy Talecris Biotherapeutics for $3.1 billion. Report

> Anthera Pharmaceuticals has completed a $19 million venture round and plans to use the funds to advance its work on anti-inflammatory drugs. Report

> Geron and Exeter Life Sciences have created a joint venture--Start Licensing Inc.--to manage intellectual property rights revolving around animal reproductive technology, a field that includes animal cloning. Report

> Diakron Pharmaceuticals has simultaneously struck a pair of deals to in-license a Phase I oral anti-coagulant therapy from Merck while signing India's Orchid Chemicals as a development partner for the program. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.